PriCells: Recombinant Human Thrombopoietin (rhTPO)

Thrombopoietin (TPO), the c-Mpl ligand, is the primary physiologic regulator of megakaryocyte and platelet development.

TPO is synthesized primarily in the liver as a single 353-amino acid precursor protein. On removal of the 21-amino acid signal peptide, the mature molecule consists of 2 domains: a receptor-binding domain that shows considerable homology to erythropoietin and a carbohydrate-rich carboxy-terminus of the protein that is highly glycosylated and important in maintaining protein stability.

TPO in treating chronic nonchemotherapy-induced thrombocytopenia associated with myelodysplastic syndromes, idiopathic thrombocytopenic purpura, thrombocytopenia due to human immunodeficiency virus, and liver disease.

TPO is effective in reducing surgical thrombocytopenia and bleeding, ex vivo expansion of pluripotent stem cells, and as a radioprotectant.

Purify: 90%, as determined by SDS-PAGE analysis

Species: Human

Activity: 0.5 ng/ml

Bioassay: Proliferation

Product Size: 1μg, 10μg, 100μg

Protein Form: recombinant human

Purify Grade: Carrier-Free

Protein Family: Growth Factors

Endotoxin Level: <1EU/ml

Protein Subtype: TPO

Molecular Weight: 80-85 kDa, glycosylated

Protein Length or portion (a.a): 332 aa

Negative test: HIV-1, HBV, HCV, Mycoplasmas, Bacteria, yeast, and fungus

Expression and Purification: Recombinant human Thrombopoietin is expressed in a human cell expression system and purified via sequential chromatography.

Contents and Storage: Store this lyophilized preparation at -20°C, preferably desiccated. Upon reconstitution, apportioninto working aliquots and store at -20°C. Avoid repeated freeze/thaw cycles.

Expiration Date: Expires one year from date of receipt when stored as instructed.

These products are for research use only and are not intended for human or animal diagnostic, or therapeutic.